The Phase 3 trial is called EXTINGUISH ARDS. For Austin-based Direct Biologics, it’s the final clinical gate before a potential commercial launch for its lead product, ExoFlo, aimed at a severe lung injury condition with a market valued at $941 million [CB Insights]. The company’s pitch is built on extracellular vesicles, tiny messengers derived from human bone marrow stem cells, packaged as an off-the-shelf biologic.
The Exosome Wedge
Direct Biologics is a biologic therapy manufacturer operating under cGMP conditions. Its product contains a cocktail of growth factors and exosomes isolated from mesenchymal stem cells [BCC Research]. For acute respiratory distress syndrome (ARDS), a condition with a mortality rate that can exceed 40%, the clinical need is acute. In 2021, the FDA granted ExoFlo Regenerative Medicine Advanced Therapy (RMAT) status, which can accelerate development and review [Direct Biologics]. This cleared the way for the ongoing Phase 3 trial, which is enrolling hospitalized patients with moderate-to-severe ARDS [Direct Biologics].
Funding the Pivot
Public disclosures point to a complex funding picture. The company has raised an estimated $35.1 million to date [StartupSeeker]. A 2022 SEC filing shows a $5 million investment from IB Investments 1 LLC as part of a larger offering [SEC.gov, 2022]. Market reports suggest the full target for that offering is $100 million [MarketScreener].
Leadership and the Clinical Push
Co-founders Mark Adams and Joe Schmidt remain on the board. In early 2020, Jodi Gurney was named Chief Executive Officer [PR Newswire, Mar 2020]. Tim Moseley, PhD, serves as Chief Technology Officer [LifeScienceHistory]. The company has FDA clearance for a Phase 1b/2a trial of ExoFlo for perianal fistulizing Crohn’s disease [LinkedIn] and is running a Phase 1 trial for ulcerative colitis [CGTlive®]. It also markets AmnioWrap™, a placental allograft product [AP News].
| Key Leadership | Role |
|---|---|
| Jodi Gurney | Chief Executive Officer |
| Mark Adams | Co-Founder, Board Member |
| Tim Moseley, PhD | Chief Technology Officer |
| John Vacalis | President & Chief Legal Officer |
Where the Wheels Could Come Off
The road to an FDA approval is littered with Phase 3 failures, and ARDS is a difficult endpoint. The competitive landscape is dense, featuring established players like Boehringer Ingelheim and Genentech, as well as biotech specialists such as Athersys, Healios, and Mesoblast Limited. Direct Biologics’s differentiation rests on its exosome approach and RMAT designation, but the final efficacy and safety data remain unproven at the pivotal trial scale.
The Next Twelve Months
For Direct Biologics, 2025 is a year defined by clinical enrollment and capital formation. Progress in the EXTINGUISH ARDS trial will be the primary signal for investors. Concurrently, closing the anticipated $100 million funding round would secure the balance sheet needed to see the trial through to data readout. The question for the next check-writers is whether the exosome approach can clear a bar that has defeated so many others, and if the data from the 102-patient Phase 2 trial can be replicated in a broader, all-cause ARDS population [Clinical Trials Arena].